<?xml version="1.0" encoding="UTF-8"?>
<p>It is beyond the scope of this communication to discuss the various technical challenges inherent in developing a safe and efficacious vaccine for coronavirus infections in humans. There are clearly challenges to this endeavorâ€”protective antibodies to coronaviruses are not long-lasting, tissue damage has been reported to occur as a result of exposure to SARS-CoV, development of animal models that closely resemble human infection are limited, and the extensive time and expense necessary to perform clinical trials in humans, to name a few [
 <xref rid="B66-viruses-12-00194" ref-type="bibr">66</xref>,
 <xref rid="B67-viruses-12-00194" ref-type="bibr">67</xref>,
 <xref rid="B68-viruses-12-00194" ref-type="bibr">68</xref>].
</p>
